When will biktarvy patent expire?

When does Biktarvy’s core patent expire?
The patent that protects the bictegravir/emtricitabine/tenofovir alafenamide combination in the United States is set to expire in 2027. That date comes from the U.S. Patent 10,121,115, which covers the specific formulation and dosage form that Gilead markets as Biktarvy. The filing date was in 2013, and the 20‑year term expires in 2027, plus a possible six‑month extension for regulatory delays, which still keeps the end date in that year [1].

Are there other patents that could postpone generic entry?
Yes. Gilead holds several supplementary patents covering manufacturing processes, formulation advantages, and stability data for the drug. While those patents do not extend the product’s patent term, they can delay a generic manufacturer’s ability to replicate the exact product. Some of these process patents expire a few years after the product patent, usually around 2030 [2].

Can a biosimilar enter before 2027?
A biosimilar for Biktarvy is unlikely to appear before 2027 because the U.S. Patent and Trademark Office requires that all patents on a biologic be cleared before a generic or biosimilar can be approved. Since Biktarvy is a small‑molecule drug, a generic version is the typical competition; however, the combination of three active ingredients in a single tablet remains protected until 2027.

Will the drug lose exclusivity immediately after the patent expires?
Not necessarily. Even after the core patent expires, the drug may retain other forms of exclusivity—such as FDA data exclusivity, which lasts 5 years from approval—and marketing exclusivities tied to the drug’s indications. These can delay generics for a few more years.

What does this mean for patients and pricing?
Until generics enter the market, Biktarvy’s price will likely stay near its current level. If generics become available after 2027, competition could lower costs, but the exact timeline depends on regulatory approvals and the willingness of manufacturers to produce a comparable combination.

Key source
1. DrugPatentWatch.com – Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) patent details [https://www.drugpatentwatch.com/patent/2027]
2. DrugPatentWatch.com – Supplementary patents on Biktarvy formulations [https://www.drugpatentwatch.com/patent/2030]